D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Ryanair
RYAAY
$31.1B
| $4.51M | ﹤0.01% |
97,958
+79,500
| +431% | +$3.43M |
|
|
FMIVU
1802
DELISTED
Forum Merger IV Corporation Unit
FMIVU
| $4.5M | ﹤0.01% |
+454,686
| New | +$4.52M |
|
1803
CALL
Royal Bank of Canada
RY
$295B
| $4.5M | ﹤0.01% |
48,800
-1,200
| -2% | -$104K |
|
1804
PUT
CME Group
CME
$93.5B
| $4.49M | ﹤0.01% |
22,000
+2,000
| +10% | +$394K |
|
|
TRCA.U
1805
DELISTED
Twin Ridge Capital Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
TRCA.U
| $4.48M | ﹤0.01% |
+450,000
| New | +$4.49M |
|
|
DFS
1806
CALL
DELISTED
Discover Financial Services
DFS
| $4.47M | ﹤0.01% |
47,100
-11,300
| -19% | -$1.07M |
|
1807
American Express Global Business Travel
GBTG
$4.92B
| $4.47M | ﹤0.01% |
+451,679
| New | +$4.73M |
|
|
HTLF
1808
DELISTED
Heartland Financial USA, Inc.
HTLF
| $4.47M | ﹤0.01% |
88,930
+58,665
| +194% | +$2.76M |
|
|
RUBY
1809
DELISTED
Rubius Therapeutics, Inc
RUBY
| $4.47M | ﹤0.01% |
168,575
+7,478
| +5% | +$109K |
|
1810
Agios Pharmaceuticals
AGIO
$2.14B
| $4.46M | ﹤0.01% |
86,358
-99,672
| -54% | -$4.94M |
|
1811
Viatris
VTRS
$20.8B
| $4.46M | ﹤0.01% |
318,935
-962,408
| -75% | -$15.7M |
|
1812
Frontdoor
FTDR
$5.22B
| $4.45M | ﹤0.01% |
82,814
-20,112
| -20% | -$1.1M |
|
|
HEXO
1813
DELISTED
HEXO Corp. Common Shares
HEXO
| $4.45M | ﹤0.01% |
+49,188
| New | +$4.79M |
|
1814
EastGroup Properties
EGP
$11.3B
| $4.45M | ﹤0.01% |
31,057
+20,316
| +189% | +$2.85M |
|
|
CIR
1815
DELISTED
CIRCOR International, Inc
CIR
| $4.45M | ﹤0.01% |
127,660
+51,038
| +67% | +$1.83M |
|
1816
Xeris Biopharma Holdings
XERS
$1.42B
| $4.44M | ﹤0.01% |
985,316
+91,718
| +10% | +$495K |
|
1817
Jack Henry & Associates
JKHY
$11.2B
| $4.44M | ﹤0.01% |
29,249
-249,310
| -89% | -$38M |
|
1818
PUT
Illumina
ILMN
$29.1B
| $4.42M | ﹤0.01% |
11,822
-24,775
| -68% | -$10.1M |
|
1819
CALL
C.H. Robinson
CHRW
$20.1B
| $4.41M | ﹤0.01% |
46,200
-200
| -0.4% | -$18.7K |
|
1820
Veru
VERU
$35.6M
| $4.41M | ﹤0.01% |
+40,908
| New | +$5.15M |
|
1821
First Financial Bancorp
FFBC
$3.55B
| $4.4M | ﹤0.01% |
183,483
-27,632
| -13% | -$609K |
|
1822
CALL
Dave & Buster's
PLAY
$360M
| $4.39M | ﹤0.01% |
+91,700
| New | +$3.58M |
|
1823
V2X
VVX
$2.81B
| $4.39M | ﹤0.01% |
82,122
-73
| -0.1% | -$4K |
|
1824
Intuitive Surgical
ISRG
$130B
| $4.38M | ﹤0.01% |
17,799
-63,750
| -78% | -$16M |
|
|
BLUE
1825
DELISTED
bluebird bio
BLUE
| $4.38M | ﹤0.01% |
11,207
-3,350
| -23% | -$1.65M |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.